Top 10 CRISPR Stocks to Buy Now

Page 7 of 10

4. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 29

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best CRISPR stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s supplemental update to its Phase 1 CTX310 trial findings, H.C. Wainwright reaffirmed its Buy rating and $65 price target on the company on June 27.

According to the latest results, CTX310, an in vivo ANGPTL3 knockout therapy, continues to exhibit peak reductions of up to 82% in triglycerides and around 86% in LDL cholesterol at dose level four. These reductions were made without causing any discernible alterations in liver enzyme levels, preserving a safety profile in line with previous research.

However, H.C. Wainwright pointed out that baseline cholesterol control measurements, the existence of only one patient at the highest dose level, and illness variability continue to limit analysis. Future updates, including disease-specific efficacy data, response levels over time, and reduced error values, would be of interest to the firm.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification.

Page 7 of 10